Key Takeaways
- 40% revenue growth, battery roadmap locked: Q3 FY23 revenue grew 40% YoY, and the board approved a detailed battery chemicals capacity build-out through September 2025, funded by a ~₹450 crore CAPEX program.
- Lithium prices inflated the top line, compressed margins: The 85% YoY jump in inorganic chemicals revenue was significantly driven by elevated lithium prices, which simultaneously pressured gross margins and kept EBITDA growth at 27% YoY.
- Battery chemicals is now a subsidiary play: Management is carving out the battery chemicals business into a wholly-owned subsidiary, citing different CAPEX/OPEX profiles, distinct skill sets, and a 15% lower corporate tax rate for newer entities.
- Customer validation is early but encouraging: First electrolyte and international salt samples have met the majority of customer criteria, and management is engaging with ~15 potential domestic electrolyte customers, though firm contracts await pilot facility approval.
- What to watch next quarter: Whether the pilot electrolyte facility relocation completes on schedule, the pace of customer contract conversions post-approval, and any stabilization in lithium prices that would clarify the 16.5%–19% EBITDA margin range.
Battery Chemicals: Capacity, Structure & Strategy
- Board-approved capacity roadmap: Electrolyte capacity expands to 5,000 MT (operational by June 2024), specialty lithium salts to 1,000 MT (operational by June 2024), and a greenfield expansion adds another 5,000 MT electrolyte and 1,000 MT specialty lithium salts (operational by September 2025).
- Subsidiary structure: A wholly-owned subsidiary will house the battery chemicals business, providing a clear operational view, accommodating future expansion beyond initial requirements, and capturing a 15% lower corporate tax rate.
- Phased execution: The 1,000 MT electrolyte pilot plant (relocated from Vadodara to Dahej SEZ) comes first, followed by brownfield expansion to 5,000 MT and salt capacity increase at Dahej in parallel, with the greenfield site running concurrently but taking longer.
- Greenfield site is domestic, not SEZ: The greenfield site will be domestic-focused, with land not yet finalized, and is being considered as the main battery chemicals site beyond the initial two-year requirements.
- Capacity is the bare minimum: Announced capacities only address projected India electrolyte demand; management acknowledges that by FY30, overall demand could reach 100,000–250,000 MTPA versus the current planned 10,000 MT, requiring further capacity increases beyond FY27/FY28.
- Lithium salt self-sufficiency: The majority of lithium salts will be made in-house, with slight excess capacity (2,000 MT vs. 1,000–1,500 MT needed) held as a buffer; any excess can target international demand.
- Specialty additives approach: Some additives will be manufactured in-house, while specialized ones may be sourced from Japan or Korea until scale justifies domestic production; excess capacity will be sold to third parties if available.
Dr. Harin Kanani: "What we have said so far is, first of all, in the battery materials, we have only assumed India electrolyte demand currently. Of course, we keep the international demand as a backup, but we have not taken any significant number from that into our projections."
Customer Traction & Competitive Positioning
- Sample evaluation progress: Several customers have started evaluating Neogen samples for both electrolyte and international salt applications, with some providing very positive feedback that first samples meet the majority of their criteria.
- Customer pipeline: Management is working with almost 15 potential customers for electrolytes within India and a couple outside, with several expected to start by 2024, especially participants in the PLI Scheme.
- Contract timing: Firm contracts for electrolytes are expected post pilot facility approval, in the June to December period; conditional contracts may come earlier, subject to final qualification.
- Domestic moat vs. international headwinds: In the domestic electrolyte market, Neogen holds advantages in local logistics and benefits over China; internationally, the company competes head-to-head with Chinese scale, relying solely on a China Plus One premium whose willingness customers have not yet demonstrated.
- International salts as Plan B: International salt sales are currently a backup strategy; management will assess this path only after trial production starts, commercial supplies begin, the cost structure versus Chinese competitors is understood, and customer willingness to pay a China Plus One premium becomes clear.
- Dahej site drawing customer visits: As the Dahej facility stabilizes, management is seeing many customer visits from pharma, agro, aroma, and other industries, with some discussing large single-molecule projects in the ₹50–100 crore or ₹100 crore+ range.
Dr. Harin Kanani: "Several of these customers have started evaluating Neogen samples and some of them have given very positive feedback that, the first samples submitted by us meet majority of their criteria. This is for both, our electrolyte as well as international salt customers with whom we have worked."
Existing Business Performance
- Organic chemicals: 30% YoY growth in Q3 FY23, driven by increased plant utilization and firm demand in crucial end-user industries; 15,000 litres of new specialty organic chemicals capacity commissioned during the quarter, with the remaining 45,000 litres expected by September 2023.
- Inorganic chemicals: 85% YoY jump steered by a mix of realization improvement (elevated lithium prices) and volume expansion; additional capacity from 1,200 MT to 2,400 MT at Dahej is on track to commission by May/June 2023.
- CSM segment: Advanced intermediates and custom synthesis manufacturing progressing well, with 8 new customers added in 9M FY23 across geographies and industries, taking the total to over 39 customers; revenue contribution currently ~15%, targeted at 20% by FY24.
- CSM commercialization: Projects that moved from pilot to commercial have started supplying, with some to begin in Q4; aroma and flavors & fragrances projects remain under discussion and are expected to contribute revenue next financial year.
- Profitability: PAT grew 40% YoY, demonstrating operational efficiency, though marginally impacted by high depreciation from additional new capacities and a surge in finance costs from rising interest rates.
- Working capital improvement: Absolute working capital and inventory remain similar to six-month levels, but with revenues increasing, the working capital cycle in days is improving; target is 120–125 days by FY24.
Margins & Cost Structure
- Gross margin pressure: The QoQ and YoY dip in gross margin was driven by elevated lithium prices and product mix in the quarter; even within CSM, longer-duration projects carry different gross margin profiles, making sequential changes a function of molecule mix.
- Stable-state gross margin range: Management expects 40%–44% on a stable basis at least through FY24, though this could be higher at times unless lithium prices change dramatically.
- Battery chemicals margin expectation: At least 18.5% EBITDA margin, +/-1%, when making the full chain from lithium carbonate through salts to electrolyte; management views this as similar to making bromine derivatives, advanced intermediates, and CSM on an OEM basis.
- Consolidated EBITDA trajectory: With stable lithium prices, 18.5%–19%; with current elevated lithium prices, 16.5%–17.5%; management requests time before giving specific EBITDA targets as the battery business develops.
- Cost pass-through working: Continued high inflation in key input costs, especially lithium, has been passed on to customers, protecting absolute EBITDA which grew 27% YoY.
- Employee cost build-up: The rise in employee expenses aligns with a planned workforce enhancement across various departments.
Dr. Harin Kanani: "When we are doing all three together, we feel that it is similar to basically making bromine derivatives, making advanced intermediates and then doing CSM on an OEM basis. So, that is why we feel it has a similar margin profile."
Lithium Price & Raw Material Outlook
- Lithium will not return to historical levels: Management estimates that when demand-supply balances, lithium prices will settle at 2x–3x historical levels, though the transition timing is highly uncertain, potentially taking anywhere from 2 to 6 years.
- Jammu lithium deposits not a near-term solution: Management views the Jammu discovery positively but believes significant work remains to understand commercial viability, exact composition, concentration, and separation; this alone will not solve the lithium price issue.
- Demand-supply will eventually match: Management's base case is that demand and supply will ultimately catch up, bringing prices down from current elevated levels, but the path and pace remain unpredictable.
Dr. Harin Kanani: "What we are estimating is that when the dust settles and when lithium demand-supply is balanced, it might be 2x or 3x of what were historical lithium prices. That transition when it will happen, that is very difficult to predict. Will it happen in 2 years, will it take 4 years, or will it take 6 years to reach those levels is very difficult to predict."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Organic chemicals capacity completion | Remaining 45,000 litres commissioned | By September 2023 |
| Inorganic chemicals capacity doubling | 1,200 MT to 2,400 MT at Dahej | By May/June 2023 |
| Battery chemicals pilot capacity | 400 MTPA specialty lithium salts and additives | By June 2023 |
| Electrolyte pilot plant | 1,000 MT at Dahej SEZ | By August/September 2023 |
| Electrolyte capacity expansion | 5,000 MT operational | By June 2024 |
| Specialty lithium salts expansion | 1,000 MT operational | By June 2024 |
| Greenfield expansion | Additional 5,000 MT electrolyte and 1,000 MT specialty lithium salts | By September 2025 |
| Consolidated revenue target | ₹2,000–2,250 crore (>30% revenue CAGR) | By FY26/FY27 |
| Existing business revenue | ₹1,000–1,200 crore | By FY26/FY27 |
| FY24 revenue | ₹700–750 crore (standard lithium price); ~₹800–850 crore (current lithium price) | FY24 |
| CSM revenue contribution | 20% of revenue (from ~15% currently) | By FY24 |
| Working capital cycle | 120–125 days | By FY24 |
| ROE and ROCE | Much above 20% when CAPEX fully utilized | By FY27 |
| Overall CAPEX funding | ~₹450 crore, debt-equity below 1.25x | Across FY24–FY25 |
| EBITDA run rate | Targeted ₹110 crore; run rate suggests overshooting | FY23 |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue | ₹186.3 cr, +40% YoY |
| 9M FY23 revenue | ₹482.3 cr, +46% YoY |
| EBITDA | ₹30.1 cr, +27% YoY |
| 9M FY23 EBITDA | ₹79 cr, +32% YoY |
| PAT | ₹14.7 cr, +40% YoY |
| 9M FY23 PAT | ₹35.7 cr, +23% YoY |
| Organic chemicals revenue | ₹136 cr, +30% YoY |
| Inorganic chemicals revenue | ₹50 cr, +85% YoY |
| Domestic/export mix | 47% / 53% |
| CSM revenue contribution | ~15% of revenues in FY23; target 20% by FY24 |
| CSM customers | >39 engaged, 8 new added in 9M FY23 |
| CSM pipeline | 23 products, combined revenue potential of ₹2,100 cr |
| Organic reactor capacity | 466,000 litres (466 m3) total; 15,000 litres commissioned, 45,000 litres by Sep 2023 |
| Inorganic capacity expansion | 1,200 MT to 2,400 MT (30 m3 reactor), commissioning by May/Jun 2023 |
| Battery chemicals capacity (specialty lithium salts) | 400 MTPA (92 m3), commissioning by Jun 2023 |
| Electrolyte pilot capacity | 1,000 MT (enhanced from 250 MT), ready by Aug/Sep 2023 |
| Electrolyte capacity expansion (brownfield) | 5,000 MT, operational by Jun 2024 |
| Specialty lithium salts capacity expansion | 1,000 MT (232 m3), operational by Jun 2024 |
| Electrolyte capacity expansion (greenfield) | Additional 5,000 MT, total installed 10,000 MT, operational by Sep 2025 |
| Specialty lithium salts capacity expansion (greenfield) | Additional 1,000 MT, total installed ~2,000 MT, operational by Sep 2025 |
| Total CAPEX for new projects | ₹450 cr, funded 70–75% debt, balance internal accruals and equity |
| Debt-equity ceiling | Below 1.25x |
| Consolidated revenue target | ₹2,000–2,250 cr by FY26/FY27, >30% revenue CAGR from FY22 base of ₹487 cr |
| Battery chemicals revenue target | ₹1,000–1,200 cr from battery chemicals division |
| Existing business revenue potential by FY27 | ₹1,050 cr, implying 13–15% CAGR |
| FY24 revenue target | ₹700–750 cr on standard lithium price; ~₹800–850 cr at current lithium price |
| EBITDA margin expectation (battery chemicals) | 18.5% ±1%; base case 17.5% in models |
| Gross margin range | 42% ±2% (40–44% on stable basis) |
| ROE/ROCE projection (fully utilized by FY27) | Much above 20% |
| Working capital cycle target | 120–125 days by FY24 |
| FY23 EBITDA target | ₹110 cr; run rate suggests overshooting |
| Lithium price context | 6x–8x historical levels; expected to settle at 2x–3x |